Why the study?
Can [18F]Fluoro-L-DOPA PET/CT localize and determine the type of congenital hyperinsulinism preoperatively?
Can [18F]Fluoro-L-DOPA PET/CT localize and determine the type of congenital hyperinsulinism preoperatively?
[18F]Fluoro-L-DOPA PET/CT is a useful noninvasive imaging modality for preoperatively distinguishing between diffuse and focal forms of congenital hyperinsulinism.
Answers are grounded in this paper and cite their sources.
May support preoperative [18F]Fluoro-L-DOPA PET/CT in congenital hyperinsulinism; hypothesis-generating and requires prospective validation.
Congenital hyperinsulinism can be divided into diffuse or focal form. The treatment and outcome depend on distinguishing between the 2 forms. Pancreatic venous sampling was the only method available to localize the insulin secretion. [F]Fluoro-levodopa, 3,4-dihydroxy-L-phenylalanine positron emission tomography/computed tomography is a noninvasive imaging investigation and increasingly used to determine the type of hyperinsulinism preoperatively. We present a case of diffuse form of congenital hyperinsulinism demonstrated by the [F]levodopa, 3,4-dihydroxy-L-phenylalanine positron emission tomography/computed tomography preoperatively and review the literature.
No takes yet. Share an insight, caveat, or question.
Subramaniam et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: